肠内营养粉对老年稳定期COPD患者肺功能及BODE指数的影响

doi:10.11958/20222117

天津医药 ›› 2023, Vol. 51 ›› Issue (11): 1232-1236.doi: 10.11958/20222117

肠内营养粉对老年稳定期COPD患者肺功能及BODE指数的影响

朱鹏飞(), 聂晓红^△(), 周倩, 张美凤, 姚梦蝶, 周晴, 肖祝

成都医学院第二附属医院（核工业四一六医院）呼吸与危重症医学科（邮编610051）

收稿日期:2023-02-12 修回日期:2023-06-14 出版日期:2023-11-15 发布日期:2023-11-07
通讯作者: ^△E-mail：xhnie1226@sina.com
作者简介:朱鹏飞（1986），男，主治医师，主要从事呼吸系统疾病方面研究。E-mail：xlxz1986@126.com
基金资助:
四川养老与老年健康协同创新中心科研项目(YLZBZ2026)

Effects of enteral nutrition on pulmonary function and BODE index in elderly patients with stable chronic obstructive pulmonary disease

ZHU Pengfei(), NIE Xiaohong^△(), ZHOU Qian, ZHANG Meifeng, YAO Mengdie, ZHOU Qing, XIAO Zhu

Department of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital of Chengdu Medical College (the 416 Hospital of Nuclear Industry), Chengdu 610051, China

Received:2023-02-12 Revised:2023-06-14 Published:2023-11-15 Online:2023-11-07
Contact: ^△E-mail：xhnie1226@sina.com

朱鹏飞, 聂晓红, 周倩, 张美凤, 姚梦蝶, 周晴, 肖祝. 肠内营养粉对老年稳定期COPD患者肺功能及BODE指数的影响[J]. 天津医药, 2023, 51(11): 1232-1236.

ZHU Pengfei, NIE Xiaohong, ZHOU Qian, ZHANG Meifeng, YAO Mengdie, ZHOU Qing, XIAO Zhu. Effects of enteral nutrition on pulmonary function and BODE index in elderly patients with stable chronic obstructive pulmonary disease[J]. Tianjin Medical Journal, 2023, 51(11): 1232-1236.

摘要/Abstract

摘要：

目的探讨肠内营养粉对老年稳定期慢性阻塞性肺疾病（COPD）患者肺功能及BODE指数的影响。方法选取116例老年稳定期COPD患者，按照微型营养评估（MNA）评分分为营养正常组（MNA>23.5分，24例）、营养不良风险组（17.0分≤MNA≤23.5分，65例）和营养不良组（MNA<17.0分，27例）；92例营养不良风险及营养不良者随机均分为对照组（常规治疗）和试验组（常规治疗基础上予肠内营养粉剂）；将试验组分为A组（17.0分≤MNA≤23.5分，33例）和B组（MNA<17.0分，13例）2个亚组。入院时及治疗3个月后，分别比较各组体质量指数（BMI）、第1秒用力呼气容积（FEV₁）、FEV₁占预计值的百分比（FEV₁pred%）、FEV₁/FVC、6 min步行距离（6MWD）、改良版英国医学研究委员会呼吸问卷（mMRC）评分及BODE指数等指标差异。结果与营养正常组比较，营养不良风险组BMI、6MWD和MNA评分降低，营养不良组女性比例、BMI、FEV₁、FEV₁pred%、6MWD和MNA评分降低，mMRC评分和BODE指数均升高（P<0.05）；营养不良组BMI、FEV₁和MNA评分低于营养不良风险组（P<0.05）。治疗3个月后，试验组BMI、FEV₁、FEV₁pred%、6MWD和MNA评分升高，mMRC评分和BODE指数降低，且试验组6MWD和MNA评分高于对照组，mMRC评分和BODE指数低于对照组（P<0.05）。治疗3个月后，A组BMI、FEV₁、6MWD和MNA评分升高，mMRC评分和BODE指数降低；B组BMI、FEV₁、FEV₁pred%、6MWD和MNA评分升高，BODE指数降低（P<0.05）；B组BMI、FEV₁和MNA评分低于A组，mMRC评分和BODE指数高于A组（P<0.05）。COPD患者入院时MNA评分与BMI、FEV₁、FEV₁pred%、FEV₁/FVC、6MWD呈正相关，与mMRC评分和BODE指数呈负相关（P<0.05）。结论肠内营养粉可改善老年稳定期营养不良COPD患者肺功能及BODE指数。

关键词: 肺疾病, 慢性阻塞性, 营养不良, 肠道营养, 肺功能, BODE指数

Abstract:

Objective To explore the effect of enteral nutrition powder on pulmonary function and BODE index in elderly patients with stable chronic obstructive pulmonary disease (COPD). Methods A total of 116 elderly stable COPD patients were selected and divided into the normal nutrition group (MNA>23.5 points, 24 cases), the malnutrition risk group (17.0 points ≤ MNA ≤ 23.5 points, 65 cases) and the malnutrition group (MNA<17.0 points, 27 cases) based on the MNA score. Ninety-two patients with malnutrition risk and malnutrition were randomly divided into the control group (routine treatment) and the experimental group (enteral nutrition powder was given on the basis of routine treatment). The experimental group was divided into two subgroups (MNA<17.0 points，27 cases): group A (17.0 points ≤ MNA ≤ 23.5 points, 33 cases) and group B (MNA<17.0 points, 13 cases). At admission and 3 months after treatment, differences in body mass index (BMI), forced expiratory volume at 1 second (FEV₁), percentage of FEV₁ to predicted value (FEV₁pred%), FEV₁/FVC, 6-minute walking distance (6MWD), modified British Medical Research Council Respiratory Questionnaire (mMRC) and BODE index were compared between groups. Results Compared with the group with normal nutrition, the BMI, 6MWD and MNA scores were decreased in the malnutrition risk group, while the proportion of women in the malnutrition group, BMI, FEV₁, FEV₁pred%, 6MWD and MNA scores were decreased, and the mMRC and BODE index were increased (P<0.05). BMI, FEV₁ and MNA scores were lower in the malnutrition group than those of the malnutrition risk group (P<0.05). After 3-month treatment, BMI, FEV₁, FEV₁pred%, 6MWD and MNA scores were increased in the experimental group, while mMRC and BODE index decreased. The 6MWD and MNA scores were higher in the experimental group than those of the control group, while mMRC and BODE index were lower than those of the control group (P<0.05). After 3 months of treatment, BMI, FEV₁, 6MWD and MNA scores increased in the group A, while mMRC and BODE index decreased. BMI, FEV₁, FEV₁pred%, 6MWD and MNA scores increased in the group B, while BODE index decreased (P<0.05). BMI, FEV₁ and MNA scores were lower in the group B than those of the group A, while mMRC and BODE index were higher than those of the group A (P<0.05). The MNA score of COPD patients at admission was positively correlated with BMI, FEV₁, FEV₁pred%, FEV₁/FVC and 6MWD, while negatively correlated with mMRC and BODE index (P<0.05). Conclusion Enteral nutrition powder could improve lung function and BODE index in elderly stable malnutrition COPD patients.

Key words: pulmonary disease, chronic obstructive, malnutrition, enteral nutrition, pulmonary function, BODE index

中图分类号:

R563.1

图/表 3

参考文献 25

[1]	HALPIN D M G, CRINER G J, PAPI A, et al. Global initiative for the diagnosis,management,and prevention of chronic obstructive lung disease. the 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2021, 203(1):24-36. doi:10.1164/rccm.202009-3533SO.
[2]	FERRERA M C, LABAKI W W, HAN M K. Advances in chronic obstructive pulmonary disease[J]. Annu Rev Med, 2021, 72:119-134. doi:10.1146/annurev-med-080919-112707.
[3]	KORKMAZ C, DEMIRBAS S, VATANSEV H, et al. Effects of comprehensive and intensive pulmonary rehabilitation and nutritional support on quality of life and functional status in patients with chronic obstructive pulmonary disease[J]. J Int Med Res, 2020, 48(4):300060520919567. doi:10.1177/0300060520919567.
[4]	王玺, 张琰, 白俊, 等. 肠内营养粉联合甲地孕酮治疗101例恶性肿瘤相关营养不良[J]. 肿瘤学杂志, 2020, 26(5):461-464.
	WANG X, ZHANG Y, BAI J, et al. Effect of enteral nutrition power combined with megestrol acetate in the treatment of 101 cases with cancer related- malnutrition[J]. Journal of Chinese Oncology, 2020, 26(5):461-464. doi:10.11735/j.issn.1671-170X.2020.05.B019.
[5]	SARKER H N, ALAM M M, VADURY S C, et al. Use of BODE index to assess prognosis of patients with COPD[J]. Mymensingh Med J, 2022, 31(2):443-448.
[6]	SINGH D, AGUSTI A, ANZUETO A, et al. Global Strategy for the diagnosis,management,and prevention of chronic obstructive lung disease:the GOLD science committee report 2019[J]. Eur Respir J, 2019, 53(5):1900164. doi:10.1183/13993003.00164-2019.
[7]	HSU M F, HO S C, KUO H P, et al. Mini-nutritional assessment(MNA)is useful for assessing the nutritional status of patients with chronic obstructive pulmonary disease:a cross-sectional study[J]. COPD, 2014, 11(3):325-332. doi:10.3109/15412555.2013.863274.
[8]	ERTAN YAZAR E, NIKSARLIOGLU E Y, YIGITBAS B, et al. How to utilize CAT and mMRC scores to assess symptom status of patients with COPD in clinical practice?[J]. Medeni Med J, 2022, 37(2):173-179. doi:10.4274/MMJ.galenos.2022.06787.
[9]	LI C L, CHANG H C, TSENG C W, et al. Comparison of BODE and ADO indices in predicting COPD-related medical costs[J]. Medicina, 2023, 59(3):577. doi:10.3390/medicina59030577.
[10]	李薇, 杨汀, 王辰. 中国慢性阻塞性肺疾病防治现状及进展[J]. 中国研究型医院, 2020, 7(5):1-5.
	LI W, YANG T, WANG C. Current situation and progress of chronic obstructive pulmonary disease prevention and treatment in China[J]. J Chin Res Hosp, 2020, 7(5):1-5. doi:10.19450/j.cnki.jcrh.2020.05.001.
[11]	康健. 重视慢性阻塞性肺疾病合并症和并发症的诊治[J]. 中国实用内科杂志, 2020, 40(10):793-794.
	KANG J. Pay attention to the diagnosis and treatment of comorbidity and complication of chronic obstructive pulmonary disease[J]. Chinese Journal of Practical Internal Medicine, 2020, 40(10):793-794. doi:10.19538/j.nk2020100101.
[12]	MATKOVIC Z, CVETKO D, RAHELIC D, et al. Nutritional status of patients with chronic obstructive pulmonary disease in relation to their physical performance[J]. COPD, 2017, 14(6):626-634. doi:10.1080/15412555.2017. 1386643.
[13]	NGUYEN H T, COLLINS P F, PAVEY T G, et al. Nutritional status,dietary intake,and health-related quality of life in outpatients with COPD[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14:215-226. doi:10.2147/COPD.S181322.
[14]	KEOGH E,、 MARK WILLIAMS E. Managing malnutrition in COPD:a review[J]. Respir Med, 2021, 176:106248. doi:10.1016/j.rmed.2020.106248.
[15]	PINZÓN-ESPITIA O L, PARDO-OVIEDO J M, IBÁÑEZ-PINILLA M. Detection of nutritional risk and hospital stay in the hospitalized elderly adult[J]. Nutr Hosp, 2021, 38(3):464-469. doi:10.20960/nh.03200.
[16]	CAO Y, LI P, WANG Y, et al. Diaphragm dysfunction and rehabilitation strategy in patients with chronic obstructive pulmonary disease[J]. Front Physiol, 2022, 13:872277. doi:10.3389/fphys.2022.872277.
[17]	DECRAMER M, JANSSENS W, MIRAVITLLES M. Chronic obstructive pulmonary disease[J]. Lancet, 2012, 379(9823):1341-1351.
[18]	高士媛, 施敏骅, 陈锐, 等. 精简微型营养评价量表预测老年慢性阻塞性肺疾病患者急性加重风险的效能评价[J]. 中华医学杂志, 2020, 100(14):1063-1067.
	GAO S Y, SHI M H, CHEN R, et al. Evaluation of the efficacy of a streamlined micro-nutrient assessment scale in predicting the risk of exacerbations in elderly patients with chronic obstructive pulmonary disease[J]. Natl Med J China, 2020, 100(14):1063-1067. doi:10.3760/cma.j.cn112137-20191030-02356.
[19]	KALUŹNIAK-SZYMANOWSKA A, KRZYMIŃSKA-SIEMASZKO R, WIECZOROWSKA-TOBIS K, et al. Optimal assessment of nutritional status in older subjects with the chronic obstructive pulmonary disease—a comparison of three screening tools used in the GLIM diagnostic algorithm[J]. Int J Environ Res Public Health, 2022, 19(3):1025. doi:10.3390/ijerph19031025.
[20]	ZHAO Y, GE N, XIE D, et al. The geriatric nutrition risk index versus the mini-nutritional assessment short form in predicting postoperative delirium and hospital length of stay among older non-cardiac surgical patients:a prospective cohort study[J]. BMC Geriatr, 2020, 20(1):107. doi:10.1186/s12877-020-1501-8.
[21]	KAMATH S, KUMAR A, PANDA S K, et al. Correlation of BODE index with quality of life in stable Chronic Obstructive Pulmonary Disease (COPD) patients - A prospective study[J]. J Family Med Prim Care, 2020, 9(11):5606-5613. doi:10.4103/jfmpc.jfmpc_735_20.
[22]	VAN IERSEL L E J, BEIJERS R J H C G, GOSKER H R, et al. Nutrition as a modifiable factor in the onset and progression of pulmonary function impairment in COPD:a systematic review[J]. Nutr Rev, 2022, 80(6):1434-1444. doi:10.1093/nutrit/nuab077.
[23]	ODENCRANTS S, BJUSTRÖM T, WIKLUND N, et al. Nutritional status,gender and marital status in patients with chronic obstructive pulmonary disease[J]. J Clin Nurs, 2013, 22(19/20):2822-2829. doi:10.1111/jocn.12222.
[24]	HUANG W J, FAN X X, YANG Y H, et al. A review on the role of oral nutritional supplements in chronic obstructive pulmonary disease[J]. J Nutr Health Aging, 2022, 26(7):723-731. doi:10.1007/s12603-022-1822-8.
[25]	张锦锋, 窦清理, 陈涓, 等. 早期肠内营养标准化治疗流程管理应用于慢性阻塞性肺疾病急性加重有创机械通气患者的临床效果分析[J]. 中华危重病急救医学, 2020, 32(1):67-71.
	ZHANG J F, DOU Q L, CHEN J, et al. Early enteral nutrition standardized treatment process management applied to the clinical effect analysis of patients with acute exacerbation of chronic obstructive pulmonary disease and invasive mechanical ventilation[J]. Chinese Emergency Medicine for Critical Illness, 2020, 32(1):67-71. doi:10.3760/cma.j.cn121430-20190927-00012.

组别	n	年龄/岁		性别（男/女）		BMI/（kg/m²）		FEV₁/L	FEV₁pred%/%
营养正常组	24	74.67±5.52		13/11		25.22±3.75		0.76±0.21	39.49±7.67
营养不良风险组	65	73.00±8.45		56/9		22.25±3.32^a		0.70±0.19	33.28±8.30
营养不良组	27	75.43±6.76		21/6^a		19.12±3.50^ab		0.60±0.24^ab	32.14±10.14^a
F或χ²		1.152		10.314^＊		20.257^＊		4.035^＊	5.626^＊
组别	FEV₁/FVC/%		6MWD/m		mMRC评分/分		BODE指数/分			MNA评分/分
营养正常组	46.87±10.71		231.92±35.44		1.58±0.50		4.63±1.01			24.69±0.70
营养不良风险组	43.05±9.18		201.23±38.35^a		2.17±0.72^a		6.11±1.43^a			19.61±1.97^a
营养不良组	43.38±8.76		192.26±47.48^a		2.48±0.85^a		6.09±1.43^a			15.30±1.08^ab
F	1.500		7.050^＊		10.375^＊		11.233^＊			67.132^＊

组别	n	年龄/岁		性别（男/女）		BMI/（kg/m²）		FEV₁/L	FEV₁pred%/%
营养正常组	24	74.67±5.52		13/11		25.22±3.75		0.76±0.21	39.49±7.67
营养不良风险组	65	73.00±8.45		56/9		22.25±3.32^a		0.70±0.19	33.28±8.30
营养不良组	27	75.43±6.76		21/6^a		19.12±3.50^ab		0.60±0.24^ab	32.14±10.14^a
F或χ²		1.152		10.314^＊		20.257^＊		4.035^＊	5.626^＊
组别	FEV₁/FVC/%		6MWD/m		mMRC评分/分		BODE指数/分			MNA评分/分
营养正常组	46.87±10.71		231.92±35.44		1.58±0.50		4.63±1.01			24.69±0.70
营养不良风险组	43.05±9.18		201.23±38.35^a		2.17±0.72^a		6.11±1.43^a			19.61±1.97^a
营养不良组	43.38±8.76		192.26±47.48^a		2.48±0.85^a		6.09±1.43^a			15.30±1.08^ab
F	1.500		7.050^＊		10.375^＊		11.233^＊			67.132^＊

组别	BMI/（kg/m²）					FEV₁/L						FEV₁pred%/%						FEV₁/FVC/%
组别	入院时	治疗后		t		入院时		治疗后		t		入院时		治疗后		t		入院时		治疗后		t
对照组	21.30±3.67	21.01±3.52		5.028^＊		0.67±0.23		0.66±0.21		3.881^＊		33.35±9.43		32.43±9.31		1.715		42.56±8.28		43.37±9.53		2.096^＊
试验组	21.29±3.67	22.18±3.49		6.719^＊		0.67±0.20		0.71±0.20		9.077^＊		32.54±8.29		34.44±9.95		2.555^＊		42.93±8.56		43.75±7.79		1.136
t	0.019	1.600				0.024		1.162				0.438		1.000				0.237		0.712
组别	6MWD/m						mMRC评分/分						BODE指数/分						MNA评分/分
组别	入院时		治疗后		t		入院时		治疗后		t		入院时		治疗后		t		入院时		治疗后		t
对照组	196.53±46.25		186.72±47.13		2.173^＊		2.28±0.81		2.39±0.65		1.946		6.09±1.43		6.13±1.19		0.423		18.29±2.62		17.96±2.67		3.710^＊
试验组	200.37±35.83		220.59±36.16		9.922^＊		2.24±0.74		1.98±0.68		3.985^＊		6.11±1.43		5.37±1.48		5.538^＊		18.39±2.69		19.03±2.49		7.576^＊
t	0.411		3.867^＊				0.270		2.974^＊				0.073		2.720^＊				0.177		2.001^＊

组别	BMI/（kg/m²）					FEV₁/L						FEV₁pred%/%						FEV₁/FVC/%
组别	入院时	治疗后		t		入院时		治疗后		t		入院时		治疗后		t		入院时		治疗后		t
对照组	21.30±3.67	21.01±3.52		5.028^＊		0.67±0.23		0.66±0.21		3.881^＊		33.35±9.43		32.43±9.31		1.715		42.56±8.28		43.37±9.53		2.096^＊
试验组	21.29±3.67	22.18±3.49		6.719^＊		0.67±0.20		0.71±0.20		9.077^＊		32.54±8.29		34.44±9.95		2.555^＊		42.93±8.56		43.75±7.79		1.136
t	0.019	1.600				0.024		1.162				0.438		1.000				0.237		0.712
组别	6MWD/m						mMRC评分/分						BODE指数/分						MNA评分/分
组别	入院时		治疗后		t		入院时		治疗后		t		入院时		治疗后		t		入院时		治疗后		t
对照组	196.53±46.25		186.72±47.13		2.173^＊		2.28±0.81		2.39±0.65		1.946		6.09±1.43		6.13±1.19		0.423		18.29±2.62		17.96±2.67		3.710^＊
试验组	200.37±35.83		220.59±36.16		9.922^＊		2.24±0.74		1.98±0.68		3.985^＊		6.11±1.43		5.37±1.48		5.538^＊		18.39±2.69		19.03±2.49		7.576^＊
t	0.411		3.867^＊				0.270		2.974^＊				0.073		2.720^＊				0.177		2.001^＊

组别	BMI/（kg/m²）					FEV₁/L						FEV₁pred%/%						FEV₁/FVC/%
组别	入院时	治疗后		t		入院时		治疗后		t		入院时		治疗后		t		入院时		治疗后		t
A组	22.30±3.09	23.15±2.86		5.297^＊		0.72±0.19		0.76±0.19		7.390^＊		33.59±7.12		35.05±9.91		1.451		43.31±8.41		43.35±7.91		1.256
B组	18.72±3.88	19.70±3.82		4.153^＊		0.54±0.17		0.58±0.17		5.143^＊		29.88±10.58		32.88±10.28		5.602^＊		41.94±9.21		42.23±7.55		0.232
t	3.292^＊	3.353^＊				3.086^＊		3.022^＊				1.377		0.661				0.486		0.828
组别	6MWD/m						mMRC评分/分						BODE指数/分						MNA评分/分
组别	入院时		治疗后		t		入院时		治疗后		t		入院时		治疗后		t		入院时		治疗后		t
A组	203.79±33.52		224.39±34.67		8.383^＊		2.12±0.70		1.85±0.62		3.464^＊		5.76±1.32		4.91±1.28		5.014^＊		19.62±2.09		20.17±1.87		5.697^＊
B组	191.69±41.27		210.92±39.45		5.125^＊		2.54±0.78		2.31±0.75		1.897		7.00±1.35		6.54±1.33		2.521^＊		15.27±0.90		16.15±1.14		5.472^＊
t	1.032		1.141				1.772		2.133^＊				2.849^＊		3.838^＊				7.214^＊		7.184^＊

肠内营养粉对老年稳定期COPD患者肺功能及BODE指数的影响

Effects of enteral nutrition on pulmonary function and BODE index in elderly patients with stable chronic obstructive pulmonary disease

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 3

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张兰英, 张福安, 刘茂茂, 陈杰, 周健, 刘钰婷, 欧阳瑶. CD1a⁺和CD83⁺树突状细胞在COPD小鼠肺组织中的分布及意义[J]. 天津医药, 2024, 52(9): 913-916.
[2]	李冬生, 秦艺榕, 乔曼, 迟航, 崔青敏, 李晓秋. 清咳平喘颗粒对COPD急性加重期的临床疗效[J]. 天津医药, 2024, 52(8): 854-857.
[3]	李梦涛, 王迁. 结缔组织病相关间质性肺病：从发病机制研究到“双达标”治疗策略[J]. 天津医药, 2024, 52(7): 673-678.
[4]	张国华, 张令令, 高兰, 罗俊丽, 申雅文, 刘磊, 王玉华. 结缔组织病相关间质性肺病合并肺癌16例临床分析[J]. 天津医药, 2024, 52(7): 687-690.
[5]	尹韦玉, 廖红丽, 刘媛. SS相关抗体在特发性炎症性肌病及其相关间质性肺炎中的临床意义[J]. 天津医药, 2024, 52(7): 695-700.
[6]	刘智超, 李霄鹤, 周红刚, 张娜. 特发性炎性肌病相关间质性肺疾病动物模型概述[J]. 天津医药, 2024, 52(7): 709-713.
[7]	赵术彤, 丁运, 李月川, 赵晓赟, 耿华, 徐美林. 轻度慢性阻塞性肺疾病的病理特征及其与炎性因子的相关性[J]. 天津医药, 2024, 52(6): 643-647.
[8]	王晶晶, 张明, 牛琛, 齐玉梅. 妊娠剧吐患者的营养状况及妊娠结局分析[J]. 天津医药, 2024, 52(5): 532-535.
[9]	冯李婷, 李莉, 谢鑫, 王星. 天津地区部分居民慢性阻塞性肺疾病影响因素分析[J]. 天津医药, 2024, 52(4): 427-431.
[10]	刘燕, 许靖, 马蕾, 曹冠亚, 赵凤德. AECOPD患者外周血EOS、D-D和NLR与肺通气功能的关系[J]. 天津医药, 2024, 52(12): 1261-1265.
[11]	屠昌明, 田园, 汪鹏程, 任鹏, 赵寅生. SII、RAR与AECOPD患者病情严重程度及并发呼吸衰竭的关系[J]. 天津医药, 2024, 52(12): 1317-1321.
[12]	于志鸿, 王小琴. 欧前胡素衍生物对COPD肺泡Ⅱ型细胞活性及耐药蛋白的影响[J]. 天津医药, 2024, 52(11): 1127-1130.
[13]	冯靖, 刘丹, 万南生, 王杰, 句仁华, 谢巍, 田羽. 导向注药套管经鼻悬吊留置伴或不伴锚定治疗肺部霉菌病的操作流程[J]. 天津医药, 2024, 52(1): 83-86.
[14]	高威, 余晨, 左伟, 吴公景, 李清智, 刘翔. 经脐单部位腹腔镜手术联合术后早期肠内营养在先天性十二指肠梗阻快速康复中的应用效果[J]. 天津医药, 2023, 51(5): 530-534.
[15]	苏振磊, 杨万春, 韩天龙. 血清CXCL9和SFRP1在AECOPD合并肺栓塞患者中的表达及对预后的影响[J]. 天津医药, 2023, 51(4): 427-431.